Eli Lilly squares up to Novo Nordisk on obesity market

Eli Lilly has just published phase III data for its obesity candidate, tirzepatide, in a respected US medical journal ­ data which shows a significant effect.
Photo: MIKE SEGAR/REUTERS / X90033
Photo: MIKE SEGAR/REUTERS / X90033
by christian bundgaard, translated by catherine brett

Brand new peer-reviewed data on Eli Lilly’s candidate tirzepatide has set the stage for a battle within the obesity market. Novo Nordisk vs Eli Lilly. Tirzepatide vs semaglutide. The US vs Denmark.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading